Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 6/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.42 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22500914 | 0.89 | TOP2A (0.47) | TOP2AATMGAKRIPK2COQ8A | |
| SCHEMBL22500935 | 0.88 | TOP2A (0.46) | TOP2AATMGAKPOLBIDO1 | |
| SCHEMBL16171227 | 0.88 | CDC25B (0.53) | DNMT1DNMT3A | |
| SCHEMBL22500967 | 0.88 | ERBB2 (0.48) | TOP2AATMGAKMAPTCYP1A2 | |
| SCHEMBL22500884 | 0.87 | TOP2A (0.52) | TOP2AATMGAKPOLBMAPT | |
| SCHEMBL22500986 | 0.85 | TOP2A (0.53) | TOP2AGAKRIPK2COQ8ANLK | |
| SCHEMBL16171225 | 0.85 | TOP2A (0.58) | TOP2APOLBMAPTJAK2JAK3 | |
| SCHEMBL22500861 | 0.82 | TOP2A (0.58) | TOP2AATMKDM4ECYP1A2CYP2C9 | |
| SCHEMBL22500911 | 0.80 | TOP2A (0.53) | TOP2AATMKDM4ECYP1A2CYP2C9 | |
| SCHEMBL16171230 | 0.79 | PIK3CA (0.47) | TOP2AATMJAK2JAK3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291502-B2 | Topoisomerase II-alpha inhibitors and methods of treating cancer using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-05-06 | — | — | US | disclosed |
| US-20230105776-A1 | Topoisomerase II-alpha Inhibitors and Methods of Treating Cancer Using the Same | UNITED STATES GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| WO-2020205991-A1 | TOPOISOMERASE II-alpha INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20140309257-A1 | TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USE AS THERAPEUTIC AGENTS | UNITED STATES GOVERNMENT | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105776-A1 | Topoisomerase II-alpha Inhibitors and Methods of Treating Cancer Using the Same | TOP2A, TOP1, TOP2B | TOP2A 1/4885ATM 733/4885GAK 601/4885 |
| US-12291502-B2 | Topoisomerase II-alpha inhibitors and methods of treating cancer using the same | TOP2A, TOP1, TOP2B | TOP2A 1/4885ATM 733/4885GAK 601/4885 |
| US-20140309257-A1 | TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USE AS THERAPEUTIC AGENTS | TOP2A, TOP1, TOP2B | TOP2A 1/4885ATM 2075/4885GAK 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.